SCHEMBL2470522

SCHEMBL2470522

CCCCCOC(=O)n1cc(F)c(N)nc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
EP300 Q09472 2/20 0.39
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 1/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ASAH1 Q13510 1/20 0.36
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
ESR1 P03372 1/20 0.35
AKR1C4 P17516 1/20 0.35
AKR1C3 P42330 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7064563 0.99 EP300 (0.41) LMNAEP300MAPTALDH1A1NPC1
SCHEMBL1224879 0.86 EP300 (0.46) LMNAEP300ALDH1A1GAAKDM4E
SCHEMBL12883796 0.86 EP300 (0.36) EP300
SCHEMBL12883799 0.84 EP300 (0.39) EP300MAPTALDH1A1RAB9AGAA
SCHEMBL7062249 0.77 ALB (0.35) EP300NPC1
SCHEMBL12883815 0.77 LMNA (0.35) LMNAMAPTALDH1A1RAB9AKDM4E
SCHEMBL1224033 0.77 ASAH1 (0.57) LMNAASAH1CYP3A4
SCHEMBL12883801 0.76 ALB (0.34) EP300
SCHEMBL2221563 0.75 ALB (0.39) LMNAEP300ALDH1A1L3MBTL1GAA
SCHEMBL1224980 0.75 TSHR (0.38) LMNAALDH1A1RAB9AL3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103897004-B Synthesis method of capecitabine 鲁南制药集团股份有限公司 2017-05-31 CN claimed
CN-103897004-A Synthesis method of capecitabine LUNAN PHARM GROUP CORP 2014-07-02 CN claimed
CN-102241721-A Method for preparing capecitabine and hydroxyl derivative intermediate thereof UNIV JIANGNAN 2011-11-16 CN claimed
EP-2241556-A1 METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD Coll Farma S.L. (ES) 2010-10-20 EP claimed
US-20100130734-A1 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-05-27 US claimed
EP-2137201-A2 PROCESS FOR PREPARING CAPECITABINE Dr. Reddy's Laboratories Ltd. (IN) 2009-12-30 EP claimed
WO-2008131062-A2 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2008-10-30 WO claimed
CN-111377988-B Capecitabine intermediate 鲁南制药集团股份有限公司 2023-06-27 CN disclosed
CN-111100172-B Cytosidine derivative and method for preparing capecitabine medicine from same 中国科学院昆明植物研究所 2023-03-17 CN disclosed
CN-111377981-B 5-deoxy-D-ribose derivative 鲁南制药集团股份有限公司 2023-03-17 CN disclosed
WO-2020140559-A1 5-DEOXY-D-RIBOSE DERIVATIVE 山东新时代药业有限公司 2020-07-09 WO disclosed
CN-111377981-A 5-deoxy-D-ribose derivative 山东新时代药业有限公司 2020-07-07 CN disclosed
CN-111377988-A Capecitabine intermediate 山东新时代药业有限公司 2020-07-07 CN disclosed
EP-2241556-A1 METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD Coll Farma S.L. (ES) 2010-10-20 EP disclosed
EP-2241556-A1 METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD Coll Farma S.L. (ES) 2010-10-20 EP disclosed
WO-2010065586-A2 PREPARATION OF CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 WO disclosed
WO-2010061402-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF CAPECITABINE KANNAN VISHWANATH (IN) 2010-06-03 WO disclosed
US-20100130734-A1 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-05-27 US disclosed
EP-2137201-A2 PROCESS FOR PREPARING CAPECITABINE Dr. Reddy's Laboratories Ltd. (IN) 2009-12-30 EP disclosed
WO-2008131062-A2 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130734-A1 PROCESS FOR PREPARING CAPECITABINE DPYD, TYMP, TYMS LMNA 2171/4885EP300 4205/4885MAPT 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.